MX2013013329A - Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos. - Google Patents
Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos.Info
- Publication number
- MX2013013329A MX2013013329A MX2013013329A MX2013013329A MX2013013329A MX 2013013329 A MX2013013329 A MX 2013013329A MX 2013013329 A MX2013013329 A MX 2013013329A MX 2013013329 A MX2013013329 A MX 2013013329A MX 2013013329 A MX2013013329 A MX 2013013329A
- Authority
- MX
- Mexico
- Prior art keywords
- tl1a
- antibodies
- inflammatory
- interaction
- autoimmune disease
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 6
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 abstract 5
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 abstract 5
- 208000027866 inflammatory disease Diseases 0.000 abstract 5
- 230000002757 inflammatory effect Effects 0.000 abstract 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
Abstract
Se proporcionan métodos y composiciones para el tratamiento de las enfermedades inflamatorias o autoinmunológicas en un sujeto, que comprenden bloquear la interacción entre DR3 y TL1A. La interacción entre DR3 y TL1A puede ser bloqueada por la reducción de la expresión de TL1A. La interacción entre DR3 y TL1A puede ser bloqueada por la administración de los anticuerpos de anti-DR3. La interacción entre DR3 y TL1A puede ser bloqueada por la administración de los anticuerpos de anti-TL1A. En los métodos de tratamiento de la enfermedad inflamatoria o autoinmunológica, la enfermedad inflamatoria o autoinmunológica puede ser una enfermedad autoinmunológica con un componente de las células T. En los métodos de tratamiento de la enfermedad inflamatoria o autoinmunológica, la enfermedad inflamatoria o autoinmunológica puede ser el asma, la esclerosis múltiple, la artritis reumatoide, la diabetes del tipo 1, la enfermedad de injerto contra huésped o la enfermedad inflamatoria del intestino (IBD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488671P | 2011-05-20 | 2011-05-20 | |
| PCT/US2012/028926 WO2012161856A1 (en) | 2011-05-20 | 2012-03-13 | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013013329A true MX2013013329A (es) | 2014-04-16 |
Family
ID=47217582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013329A MX2013013329A (es) | 2011-05-20 | 2012-03-13 | Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9068003B2 (es) |
| EP (1) | EP2709664A4 (es) |
| JP (1) | JP2014518883A (es) |
| KR (1) | KR20140104344A (es) |
| AU (1) | AU2012259312A1 (es) |
| CA (1) | CA2836898A1 (es) |
| MX (1) | MX2013013329A (es) |
| WO (1) | WO2012161856A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2536086C (en) * | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| CA2621083C (en) | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
| US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| JP2013501057A (ja) | 2009-08-03 | 2013-01-10 | ユニバーシティー・オブ・マイアミ | 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖 |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| BR112014007426B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| ES2689080T3 (es) * | 2013-01-02 | 2018-11-08 | Glenmark Pharmaceuticals S.A. | Anticuerpos que se unen a TL1A y sus usos |
| US20140193410A1 (en) | 2013-01-09 | 2014-07-10 | University Of Miami | Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| EP2996717A4 (en) * | 2013-05-17 | 2016-11-23 | Cedars Sinai Medical Center | DIFFERENT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A-MODULATED INFLAMMATION AND FIBROSIS |
| KR102295125B1 (ko) * | 2013-05-17 | 2021-08-31 | 세다르스-신나이 메디칼 센터 | 크론병과 연관된 tnfsf15와 dcr3의 변이체 |
| EP3022295A4 (en) * | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| WO2015035261A1 (en) * | 2013-09-06 | 2015-03-12 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-tl1a therapy |
| CA2929784C (en) | 2013-11-13 | 2019-11-26 | Pfizer Inc. | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
| CN106536548A (zh) * | 2014-04-28 | 2017-03-22 | 国家生物技术研究所公司 | Dr3变体及其用途 |
| EP3337509A4 (en) | 2015-08-21 | 2019-01-02 | The Children's Hospital of Philadelphia | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| WO2017077715A1 (en) * | 2015-11-02 | 2017-05-11 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| KR102481305B1 (ko) | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| SG11201903737PA (en) * | 2016-10-26 | 2019-05-30 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
| WO2020113116A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
| JP7504992B2 (ja) | 2019-10-24 | 2024-06-24 | プロメテウス バイオサイエンシーズ，インク． | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用 |
| US20220409702A1 (en) * | 2019-11-22 | 2022-12-29 | The Research Foundation For The State University Of New York | Compositions and methods for use in type 1 diabetes |
| CN119256009A (zh) * | 2022-06-17 | 2025-01-03 | 塞莱克辛有限公司 | 与人dr3特异性结合的抗体及其用途 |
| WO2024239006A1 (en) | 2023-05-17 | 2024-11-21 | Genentech, Inc. | Anti-tl1a antibody therapeutic methods |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
| WO2025076081A1 (en) | 2023-10-03 | 2025-04-10 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| EP0432216A1 (en) | 1988-09-01 | 1991-06-19 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5162215A (en) | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| CA2117903C (en) | 1992-04-28 | 1999-01-12 | Yan Yuan | Targeted cleavage of rna using eukaryotic ribonuclease and external guide sequence |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| AU7572096A (en) | 1995-11-14 | 1997-06-05 | Vimrx Holdings, Ltd. | Chimeric oligomers having an rna-cleavage activity |
| KR0161881B1 (ko) | 1995-12-05 | 1999-02-01 | 문정환 | 메모리의 데이타 읽기회로 |
| WO1997033904A1 (en) * | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6300483B1 (en) | 1997-06-19 | 2001-10-09 | Ribozyme Pharmaceuticals, Inc. | Compositions inducing cleavage of RNA motifs |
| WO1998058058A1 (en) | 1997-06-19 | 1998-12-23 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes with extended cleavage rule |
| WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| CA2536086C (en) * | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| WO2006127900A2 (en) | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
| CA2621083C (en) * | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| CA2705292C (en) | 2007-11-13 | 2016-06-21 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against tl1a |
-
2012
- 2012-03-13 WO PCT/US2012/028926 patent/WO2012161856A1/en not_active Ceased
- 2012-03-13 CA CA2836898A patent/CA2836898A1/en not_active Abandoned
- 2012-03-13 US US13/419,203 patent/US9068003B2/en active Active
- 2012-03-13 EP EP12790157.7A patent/EP2709664A4/en not_active Withdrawn
- 2012-03-13 AU AU2012259312A patent/AU2012259312A1/en not_active Abandoned
- 2012-03-13 KR KR1020137033718A patent/KR20140104344A/ko not_active Withdrawn
- 2012-03-13 JP JP2014512833A patent/JP2014518883A/ja not_active Withdrawn
- 2012-03-13 MX MX2013013329A patent/MX2013013329A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2709664A1 (en) | 2014-03-26 |
| EP2709664A4 (en) | 2015-06-10 |
| US9068003B2 (en) | 2015-06-30 |
| US20120263718A1 (en) | 2012-10-18 |
| AU2012259312A8 (en) | 2014-02-27 |
| KR20140104344A (ko) | 2014-08-28 |
| JP2014518883A (ja) | 2014-08-07 |
| AU2012259312A1 (en) | 2013-12-12 |
| CA2836898A1 (en) | 2012-11-29 |
| WO2012161856A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013013329A (es) | Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos. | |
| MY157555A (en) | Anti-cd37 antibodies | |
| WO2012031099A3 (en) | Anti-cxcl13 antibodies and methods of using the same | |
| SG10201808258SA (en) | Improved methods for manufacturing adoptive cell therapies | |
| MX2014002779A (es) | Zoom semantico. | |
| PH12015501994B1 (en) | Antibodies that bind il-23 | |
| WO2012162067A3 (en) | Cd3-binding molecules capable of binding to human and non-human cd3 | |
| JO3375B1 (ar) | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) | |
| NZ620326A (en) | Cd37 immunotherapeutic combination therapies and uses thereof | |
| WO2016011210A3 (en) | Engineered cells for adoptive cell therapy | |
| WO2010129917A3 (en) | Anti-cd100 antibodies and methods for using the same | |
| WO2013006490A3 (en) | Antibodies that specifically bind to tim3 | |
| EP3825403A3 (en) | Methods and compositions for modulating apolipoprotein(a) expression | |
| WO2012112315A3 (en) | Methods for diagnosis of kawasaki disease | |
| MX367335B (es) | Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias. | |
| IN2015DN00143A (es) | ||
| WO2013136189A3 (en) | Methods and materials for treatment of pompe's disease | |
| MX2017003841A (es) | Anticuerpos anti-il-25 y usos de los mismos. | |
| MY189494A (en) | Methods of administering beta7 integrin antagonists | |
| EP4527921A3 (en) | Renal cell populations and uses thereof | |
| WO2013106273A3 (en) | Peptides and methods of using same | |
| MA40592A (fr) | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 | |
| WO2012095743A3 (en) | Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases | |
| EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same | |
| Boca et al. | Mathematical properties of Fst between admixed populations and their parental source populations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |